References
- World Health OrganizationDengue and severe dengue2018 Available from: http://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengueAccessed September 20, 2018
- MurrayNEQuamMBWilder-SmithAEpidemiology of dengue: past, present and future prospectsClin Epidemiol2013529930923990732
- BhattSGethingPWBradyOJThe global distribution and burden of dengueNature2013496744650450723563266
- StanawayJDShepardDSUndurragaEAThe global burden of dengue: an analysis from the Global Burden of Disease Study 2013Lancet Infect Dis201616671272326874619
- Vietnam Ministry of Health-General Department of Preventive MedicineDengue fever in 20182018 Available from: http://vncdc.gov.vn/vi/tin-tuc-trong-nuoc/2354/cong-van-bo-y-te-gui-giam-doc-so-y-te-cac-tinh-thanh-pho-tiep-tuc-day-manh-cong-tac-phong-chong-dich-benh-mua-he-thu-nam-2018Accessed September 20, 2018
- World Health Organization (WHO)Guidelines for Diagnosis, Treatment, Prevention, and ControlGenevaWHO2009
- World Health Organization (WHO)Handbook for Clinical Management of DengueGenevaWHO2012
- LarsonHJJarrettCEckersbergerESmithDMPatersonPUnderstanding vaccine hesitancy around vaccines and vaccination from a global perspective: a systematic review of published literature, 2007–2012Vaccine201432192150215924598724
- SchwartzLMHalloranMEDurbinAPLonginiIMThe dengue vaccine pipeline: implications for the future of dengue controlVaccine201533293293329825989449
- World Health OrganizationDengue vaccine: WHO position paper – July 2016Wkly Epidemiol Rec2016913034936427476189
- BloomDEFanVYSevillaJPThe broad socioeconomic benefits of vaccinationSci Transl Med201810441eaaj234529769285
- ShepardDSSuayaJAHalsteadSBCost-effectiveness of a pediatric dengue vaccineVaccine2004229–101275128015003657
- DeroeckDDeenJClemensJDPolicymakers’ views on dengue fever/dengue haemorrhagic fever and the need for dengue vaccines in four Southeast Asian countriesVaccine200322112112914604579
- AmarasingheAWichmannOMargolisHSMahoneyRTForecasting dengue vaccine demand in disease endemic and non-endemic countriesHum Vaccin201069745753
- LeeJSMogasaleVLimJKA multi-country study of the household willingness-to-pay for dengue vaccines: household surveys in Vietnam, Thailand, and ColombiaPLoS Negl Trop Dis201596e000381026030922
- HadisoemartoPFCastroMCPublic acceptance and willingness-to-pay for a future dengue vaccine: a community-based survey in Bandung, IndonesiaPLoS Negl Trop Dis201379e242724069482
- GodóiIPSantosASReisEAConsumer willingness to pay for dengue vaccine (CYD-TDV, Dengvaxia®) in Brazil; implications for future pricing considerationsFront Pharmacol201784128210223
- CarlssonFJohansson-StenmanOWillingness to pay for improved air quality in SwedenAppl Econ2000326661669
- CorsoPSHammittJKGrahamJDValuing mortality-risk reduction: using visual aids to improve the validity of contingent valuationJ Risk Uncertain2001232165184
- CropperMLHaileMLampiettiJPoulosCWhittingtonDThe demand for a malaria vaccine: evidence from EthiopiaJ Dev Econ2004751303318
- HammarHJohansson-StenmanOThe value of risk-free cigarettes – do smokers underestimate the risk?Health Econ2004131597114724894
- HammitJGrahamJWillingness to pay for health protection: inadequate sensitivity to probability?J Risk Uncertainty199983362
- JohannessonMJohanssonP-OQuality of life and the WTP for an increased life expectancy at an advanced ageJ Public Econ1997652219228
- KrupnickAAlberiniACropperMAge, health and the willingness to pay for mortality risk reductions: a contingent valuation survey of Ontario residentsJ Risk Uncertain2002242161186
- LiuJTHammittJKWangJDTsouMWValuation of the risk of SARS in TaiwanHealth Econ2005141839115386665
- MahmudMContingent Valuation of Mortality Risk Reduction in Developing Countries: A Mission ImpossiblePh.D. dissertationSwedenGothenburg University2005
- PerssonUNorinderAHjalteKGralénKThe value of statistical life in transport: findings from a new contingent valuation study in SwedenJ Risk Uncertain2001232121134
- General statistics officeArea, population and population density by province2016 Available from: https://www.gso.gov.vn/default.aspx?tabid=714Accessed September 20, 2018
- Convention on the Rights of the ChildArchived October 31, 2010 at the Wayback MachineThe Policy Press, Office of the United Nations High Commissioner for Human RightsNew YorkConvention on the Rights of the Child2010
- LwangaSKLemeshowSSample size determination in health studies: a practical manual1991 Available from: http://www.who.int/iris/handle/10665/40062Accessed September 20, 2018
- Arredondo-GarcíaJLHadinegoroSRReynalesHFour-year safety follow-up of the tetravalent dengue vaccine efficacy randomized controlled trials in Asia and Latin AmericaClin Microbiol Infect201824775576329408333
- GuyBWhich dengue vaccine approach is the most promising, and should we be concerned about enhanced disease after vaccination? Questions raised by the development and implementation of dengue vaccines: example of the Sanofi Pasteur tetravalent dengue vaccineCold Spring Harb Perspect Biol2018106a02946228716892
- JacksonLARuppRPapadimitriouAWallaceDRaananMMossKJA phase 1 study of safety and immunogenicity following intradermal administration of a tetravalent dengue vaccine candidateVaccine201836273976398329789238
- YoonIKThomasSJEncouraging results but questions remain for dengue vaccineLancet Infect Dis201818212512629122464
- Sáez-LlorensXTricouVYuDImmunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2–17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled studyLancet Infect Dis201818216217029122463
- MalisheniMKhaiboullinaSFRizvanovAATakahNMurewanhemaGBatesMClinical efficacy, safety, and immunogenicity of a live attenuated tetravalent dengue vaccine (CYD-TDV) in children: a systematic review with meta-analysisFront Immunol2017886328824613
- Sáez-LlorensXTricouVYuDSafety and immunogenicity of one versus two doses of Takeda’s tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled studyLancet Infect Dis201717661562528365225
- DietrichEAOngYTStovallJLDeanHHuangCYLimited transmission potential of Takeda’s tetravalent dengue vaccine candidate by Aedes albopictusAm J Trop Med Hyg20179751423142728820715
- GuyBBriandOLangJSavilleMJacksonNDevelopment of the sanofi pasteur tetravalent dengue vaccine: one more step forwardVaccine201533507100711126475445
- CapedingMRTranNHHadinegoroSRClinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trialLancet201438499511358136525018116
- GuyBBarrereBMalinowskiCSavilleMTeyssouRLangJFrom research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccineVaccine201129427229724121745521
- FajarJKHarapanHSocioeconomic and attitudinal variables associated with acceptance and willingness to pay towards dengue vaccine: a systematic reviewArch Clin Infect Dis2017123e13914
- HarapanHAnwarSBustamamAWillingness to pay for a dengue vaccine and its associated determinants in Indonesia: a community-based, cross-sectional survey in AcehActa Trop201716624925627908746
- HaabTCMcConnellKEValuing Environmental and Natural Resources: The Econometrics of Non-Market ValuationCheltenhamEdward Elgar2002
- Kathrivera.comDengvaxia dengue vaccine now available in Watsons2017 Available from: http://www.kathrivera.com/2017/04/dengvaxia-dengue-vaccine-now-available-in-watsons.htmlAccessed September 20, 2018
- The World Bank GDP per capita (current US$)2018 Available from: https://data.worldbank.org/indicator/ny.gdp.pcap.cd?locations=vnAccessed June 5, 2018
- PhamLDPhungNHLeNTVoTQEconomic report on the cost of dengue fever in Vietnam: case of a provincial hospitalClinicoecon Outcomes Res201791828031723